Network pharmacology analysis predicted key targets of XSJ in the treatment of MASH and revealed its potential therapeutic effects through the regulation of the PI3K-AKT and TGF-β signaling pathways. Here, AKT1 is linked to metabolic dysfunction-associated steatohepatitis.